Globenewswire·2026-03-10 11:30Core Viewpoint - PMGC Holdings Inc. has initiated a preclinical study for EL-32, an engineered probiotic aimed at preserving lean muscle mass while promoting fat loss, both as a standalone therapy and in combination with GLP-1 weight loss treatments [1][3]. Group 1: Study Details - The preclinical study will utilize a diet-induced obesity (DIO) mouse model to evaluate EL-32's effectiveness [3]. - The research will assess multiple treatment groups, including standalone administration and combination therapy with semaglutide, a GLP-1 receptor agonist [3]. - Key metabolic and physiological outcomes to be evaluated include changes in body weight and fat mass, preservation of lean muscle mass, glycemic and metabolic markers, and overall body composition across treatment groups [7]. Group 2: Development Timeline - NorthStrive Biosciences has finalized study planning and anticipates the following timeline: preclinical dosing and observation period expected to occur over the next several months, followed by data analysis and CRO reporting after the study period [4][8]. - The results of the preclinical study will inform potential follow-on studies and future development strategies for EL-32 [4]. Group 3: Company Background - NorthStrive Biosciences Inc. is a subsidiary of PMGC Holdings Inc., focusing on developing innovative aesthetic medicines, with EL-22 as its lead asset targeting obesity-related muscle preservation [5]. - PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions and investments across various industries [6].